Loading...
Market
Where will Eisai and Biogen submit their next major regulatory application for Leqembi by December 31, 2024?
2
Resolution / Starting Odds
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Official announcements from Eisai, Biogen, or relevant regulatory agencies
Story
CHMP Recommends EU Rejection of Eisai and Biogen's Alzheimer's Drug Leqembi
Jul 26, 2024, 11:19 AM
On July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on lecanemab, also known as Leqembi, an Alzheimer's therapy developed by Eisai and Biogen, recommending its rejection in the European Union. This decision diverges from the stance of U.S. regulators, who have approved the medicine. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales of the drug in Europe.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
United States • 25%
European Union • 25%
South Korea • 25%
Other • 25%
Approval in another major market • 25%
Rejection in another major market • 25%
Reapplication in the EU • 25%
No major decision • 25%
Canada • 25%
Australia • 25%
Germany • 25%
Other • 25%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
